Technology | Mammography | March 28, 2018

FDA Approves New Imaging Features on Hologic 3Dimensions Mammography System

High-resolution 3-D imaging and Intelligent 2-D imaging technology now approved on Hologic’s latest digital breast tomosynthesis system

FDA Approves New Imaging Features on Hologic 3Dimensions Mammography System

March 28, 2018 — Hologic Inc. announced that Clarity HD high-resolution 3-D imaging and Intelligent 2-D imaging technology have received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) and are now available on the 3Dimensions breast tomosynthesis system. With these innovations, the system now provides higher resolution 3-D breast images for radiologists, enhanced workflow for technologists, and a more comfortable mammography experience with low-dose options for patients.

Hologic originally released the Genius 3-D Mammography exam, first approved by the FDA in 2011 on the company's 3-D Mammography system. Today, Hologic has installed more than 5,000 3-D Mammography systems throughout the United States and is continuing to help ensure insurance coverage is available for all women. More than 90 percent of women ages 40 to 75 currently have coverage for the Genius exam, and more than 16 million women in the U.S. get a Genius exam each year. The Genius exam detects 20-65 percent more invasive breast cancers and is the only mammogram approved by the FDA as superior for women with dense breasts compared to 2-D alone.1,2

The new Clarity HD high-resolution 3-D imaging technology provides what Hologic calls the industry's fastest, highest resolution 3-D images to accelerate screening and analysis, and is designed to clearly reveal subtle lesions and fine calcifications to help pinpoint cancers early. Clarity HD technology's advanced detector and innovative 3-D imaging algorithm work together to deliver high-quality 3-D images, regardless of breast size or density.

Intelligent 2-D imaging technology works with Clarity HD technology to deliver superior overall image quality, and clarity, contrast and detail at a lower dose.3,4

Another new feature, the SmartCurve breast stabilization system, is clinically proven to deliver a more comfortable mammogram without compromising image quality, workflow or dose.5 The SmartCurve system has been proven to improve comfort in 93 percent of women who reported moderate to severe discomfort with standard compression.5 It features a curved compression surface that mirrors the shape of a woman's breast to reduce pinching and allow uniform compression over the entire breast.

In addition, Quantra 2.2 Breast Density Assessment Software, also available on the 3Dimensions system, enables clinicians to provide women with consistent breast density assessments during routine breast cancer screenings. Breast density is only identifiable on a mammogram or other screening modality, and has historically been determined by the radiologist who reads the image. Through a proprietary algorithm powered by machine learning, Quantra software analyzes mammography images for distribution and texture of breast tissue, delivering clinicians accurate breast density assessment. Quantra software categorizes breasts into four density categories, in alignment with the American College of Radiology Breast Imaging-Reporting and Data System (ACR BI-RADS) Atlas 5th Edition.6,7

The Genius 3-D Mammography exam (also known as the Genius exam) is only available on a Hologic 3-D Mammography system. The Genius exam consists of a 2-D and 3-D image set, where the 2-D image can be either an acquired 2-D image or a 2-D image generated from the 3-D image set.

For more information: www.hologic.com

 

References

  1. Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions® on screening outcomes. Individual results may vary. The study found an average 41% increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1,000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D Mammography™ System versus women receiving 2D FFDM mammograms only.  
  2. FDA submissions P080003, P080003/S001, P080003/S004, P080003/S005.  
  3. Compared to C-view  
  4. Compared to 2D alone  
  5. Smith, A. Improving Patient Comfort in Mammography. Hologic WP-00019 Rev 003 (2017).  
  6. FDA 510(k) K163623  
  7. Understanding Quantra™ (Version 2.2) User Manual

Related Content

Densitas Inc., a global provider of A.I. technologies for digital mammography and breast screening, announced its partnership with Mammography Educators to offer the first artificial intelligence powered telehealth technologist training platform to support business continuity in mammography facilities.
News | Mammography | November 20, 2020
November 20, 2020 — Densitas Inc., a global provider of A.I.
Radiologists around the world will have access to a first-of-its-kind online breast density training tool designed to improve radiologists' ability to correctly identify women's breast density categories to comply with the Breast Imaging-Reporting and Data System (BI-RADS), thanks to a collaboration between DetectED-X and Volpara Health. 
News | Breast Density | November 19, 2020
November 19, 2020 — Radiologists around the world will have access to a first-of-its-kind online...
Reduces the complexity of reporting for screening and diagnostic MRI eams to deliver time-saving and patient safety benefits
News | MRI Breast | November 18, 2020
November 18, 2020 — ...
An interview with Professor Christiane Kuhl, M.D., director of radiology, University Hospital Aachen, Germany, on the effects on breast imaging in the COVID-19 era

Getty Images

Feature | Breast Imaging | November 12, 2020 | By Dave Fornell
The pandemic forced many elective procedures, including most areas of...
Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single

Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single-slice DBT image in craniocaudal view. C, Magnification of the lesion depicted in B. D, Image from SM in mediolateral oblique view. E, Single-slice DBT image in mediolateral oblique view. F, Magnification of the lesion depicted in E. Images courtesy of Radiological Society of North America

News | Breast Imaging | November 11, 2020
November 11, 2020 — ...
Hologic, Inc. announced innovative updates to its Unifi Analytics platform, a breakthrough business intelligence tool that provides mammography centers insights into technologist performance, proactive device maintenance, and business considerations.
News | Mammography | November 10, 2020
November 10, 2020 — Hologic, Inc.
Honoring essential healthcareprofessionals, Nov. 8-14
News | Radiology Imaging | November 09, 2020
November 9, 2020 — As COVID-19 continues to spre
Mammograms in a 51-year-old woman with invasive ductal carcinoma. The upper panels show the craniocaudal and the mediolateral oblique views. The lower panels show a close-up of the left breast area containing the lesion. The case is one of the false-negative cases included in the dataset. Accordingly, the initial screening assessment was a BI-RADS 2, meaning visible findings were judged as benign. After 1 year, the patient presented for another screening examination. This time, a focal asymmetry with associ

Mammograms in a 51-year-old woman with invasive ductal carcinoma. The upper panels show the craniocaudal and the mediolateral oblique views. The lower panels show a close-up of the left breast area containing the lesion. The case is one of the false-negative cases included in the dataset. Accordingly, the initial screening assessment was a BI-RADS 2, meaning visible findings were judged as benign. After 1 year, the patient presented for another screening examination. This time, a focal asymmetry with associated distortion within the left breast was noticed; the patient was recalled and diagnosed with a 1.5-cm mass in the upper outer quadrant of the left breast on the craniocaudal view (circle).

News | Mammography | November 04, 2020
November 4, 2020 — Artificial intelligen...